News Related to Relay Therapeutics

Related coverage linked through entity extraction aliases.

Relay Therapeutics Reports Revenue Growth, Narrower Loss, and FDA Breakthrough for Zovegalisib

Mar 03, 2026

Relay Therapeutics reported full-year 2025 revenue of $15.36 million and a narrowed net loss of $276.48 million, while securing FDA Breakthrough Therapy designation for lead asset zovegalisib. The company filed a $96.18 million shelf registration.

MoonLake on Track for HS BLA Submission; Relay's Zovegalisib Receives FDA Breakthrough Status

Feb 24, 2026

MoonLake Immunotherapeutics says FDA feedback indicates sufficient data to support a U.S. BLA for hidradenitis suppurativa without additional efficacy trials, while Relay Therapeutics received FDA Breakthrough Therapy designation for zovegalisib in combination with fulvestrant for PIK3CA-mutant breast cancer.